ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Electrostatic-tailored Leciplex system of ketoconazole for boosted ocular pharmacology and cytotoxicity assessment.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study aims to assess efficacy of cationic nano-vesicles, i.e. Leciplex to deliver ketoconazole into ocular surface for management of fungal infection. This research signifies influence of topical ketoconazole on fungal infection. KTN-Leciplex was fabricated by using Lipoid S 100, a cationic surface-active agent such as DDAB and a biocompatible solvent like Transcutol HP using one-step mixing procedure at 70 °C. Self-assembled lipid and cationic surfactant micelles successfully entrap KTN within their unilamellar vesicles. This fabricated KTN-Leciplex was optimized by Box-Behnken design using 3 centre points and assessed for its particle size, polydispersiblity, zeta potential, TEM, entrapment efficiency, mucoadhesion property, antifungal activity on Candida albicans (MTCC 854), cytotoxicity studies on SIRC cell lines (CCL 60-ATCC), HET-CAM test for ocular irritation, in vitro testing of drug release through dialysis membrane sac, ex vivo testing of drug permeation, ex vivo testing of corneal drug retention and histological assessment in comparison with KTN-solution on isolated goat cornea. Optimized KTN-Leciplex has a particle size of 170.5 ± 0.82 nm with a PDI value of 0.163, a zeta potential of 44.6 ± 0.36 mV, TEM images confirmed spherical-shaped nanosized (< 200 nm) vesicles and an entrapment efficiency of 91.86 ± 0.55%; statistical analysis of the mucoadhesion study identified significant change in zeta potential upon interaction with Mucin solution, suggesting possible enhanced ocular residence. The zone of inhibition for Candida albicans was found to be 24.12 ± 0.97 mm. Cytotoxicity in the SIRC (CCL 60-ATCC) cell line shows more than 76.14% of cell viability at all concentration of KTN-Leciplex with IC
Indexed as
Identifiers
41984192What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.